501439-14-1 Usage
General Description
2-Chloro-8-isopentyl-7-methyl-7,8-dihydropteridin-6(5H)-one, also known as leucopterin, is a synthetic chemical compound belonging to the class of pteridines. It is a yellow crystalline solid with a molecular formula C11H13ClN4O2 and a molecular weight of 270.70 g/mol. 2-Chloro-8-isopentyl-7-methyl-7,8-dihydropteridin-6(5H)-one is used primarily in the pharmaceutical industry as a precursor in the synthesis of various pteridine derivatives, some of which have potential biological activities as antifolates or antineoplastic agents. Additionally, leucopterin has been studied for its potential use as a fluorescent probe in biomedical research. Its chemical structure and properties make it a valuable building block for the development of new therapeutic agents and diagnostic tools.
Check Digit Verification of cas no
The CAS Registry Mumber 501439-14-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,1,4,3 and 9 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 501439-14:
(8*5)+(7*0)+(6*1)+(5*4)+(4*3)+(3*9)+(2*1)+(1*4)=111
111 % 10 = 1
So 501439-14-1 is a valid CAS Registry Number.
InChI:InChI=1/C12H17ClN4O/c1-7(2)4-5-17-8(3)11(18)15-9-6-14-12(13)16-10(9)17/h6-8H,4-5H2,1-3H3,(H,15,18)
501439-14-1Relevant articles and documents
Substituted pteridinones as p90 ribosomal S6 protein kinase (RSK) inhibitors: A structure-activity study
Backos, Donald S.,Casalvieri, Kimberly A.,Matheson, Christopher J.,Reigan, Philip
, (2020/01/28)
The activity of p90 ribosomal S6 kinase 2 (RSK2) has emerged as an attractive target for cancer therapy due to its role in the regulation of diverse cellular processes, such as cell transformation and proliferation. Several pan-RSK inhibitors have been identified with BI-D1870 and the pseudo-analogs LJH685 and LJI308 being the most selective, potent, and frequently used small molecule inhibitors. We designed and synthesized a series of pteridinones and pyrimidines to evaluate the structural features of BI-D1870 that are required for RSK2 inhibition. We have identified inhibitors of RSK2 activity, evaluated their target engagement in cells, and measured their effect on cell viability and cytotoxicity in the MOLM-13 acute myeloid leukemia (AML) cell line. The results of our studies support that RSK2 inhibition can be achieved in MOLM-13 cells without potent cytotoxicity. The structure-activity data from this study will be used as a platform to develop novel RSK2 inhibitors.
